Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1984 Mar;16(3):131–136. doi: 10.1007/BF00205418

Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK432 in melanoma patients

Etsuro Yanagawa 1, Atsushi Uchida 1,✉, Eva M Kokoschka 3, Michael Micksche 1
PMCID: PMC11039056  PMID: 6200209

Abstract

Lymphocytes and monocytes from the peripheral blood of 30 patients with malignant melanoma were tested for natural cytotoxicity against K562 cells in a 3-h 51Cr-release assay, and the effects of OK432 (a streptococcal preparation) on the cytotoxicity were examined. The lymphocyte cytotoxicity of melanoma patients was similar to that of normal donors and control patients with benign skin disease. Furthermore, the lymphocyte cytotoxicity of melanoma patients was not correlated to the stage of the disease. Similarly, lysis of K562 cells by monocytes isolated by adherence to autologous serum-coated plastic dishes in melanoma patients was comparable to that of controls and not associated with the stage of the disease. Positive monocyte reactions were recorded in 10 of 30 (33%) melanoma patients, seven of 21 (33%) normal donors and three of 10 (30%) control patients. There was no correlation between lymphocyte cytotoxicity and monocyte cytotoxicity. Overnight treatment of monocytes and lymphocytes with OK432 resulted in an increase in cytotoxicity. Significant augmentation of cytotoxicity by OK432 was observed in 28% of the monocyte samples and 86% of the lymphocyte samples, while partially purified human interferon augmented cytotoxicity in 63% of the monocyte samples and all the lymphocyte samples. These results suggest that neither lymphocyte nor monocyte cytotoxicities are depressed in melanoma patients as compared with normal donors and patients with benign disease and that OK432 has a stronger stimulatory effect on lymphocytes than on monocytes.

Keywords: Melanoma, K562 Cell, Melanoma Patient, Normal Donor, Plastic Dish

References

  • 1.Adams DO, Snyderman R. Do macrophages destroy nascent tumors? J Natl Cancer Inst. 1979;62:1341. [PubMed] [Google Scholar]
  • 2.Cameron DJ, Churchill WH. Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators. J Clin Invest. 1979;63:977. doi: 10.1172/JCI109398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cameron DJ, O'Brien P. Cytotoxicity of cancer patients macrophages for tumor cells. Cancer. 1982;50:498. doi: 10.1002/1097-0142(19820801)50:3<498::aid-cncr2820500319>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  • 4.Fischer DG, Golightly MG, Koren HS. Potentiation of the cytolytic activity of peripheral blood monocytes by lymphokines and interferon. J Immunol. 1982;130:1220. [PubMed] [Google Scholar]
  • 5.Fischer DG, Hubbard WJ, Koren HS. Tumor cell killing by freshly isolated peripheral blood monocytes. Cell Immunol. 1981;58:426. doi: 10.1016/0008-8749(81)90235-5. [DOI] [PubMed] [Google Scholar]
  • 6.Gerrard TL, Terz JJ, Kaplan AM. Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patients. Int J Cancer. 1980;26:585. doi: 10.1002/ijc.2910260510. [DOI] [PubMed] [Google Scholar]
  • 7.Hammerstøm J. Human monocyte-mediated cytotoxicity to K562 cells: Activation by lymphokines. Scand J Immunol. 1979;10:575. doi: 10.1111/j.1365-3083.1979.tb01392.x. [DOI] [PubMed] [Google Scholar]
  • 8.Herberman RB. Natural-cell-mediated immunity against tumors. New York: Academic Press; 1980. [Google Scholar]
  • 9.Hersey P, Edwards A, Milton GW, McCarthy WH. Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients. Brit J Cancer. 1978;37:505. doi: 10.1038/bjc.1978.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ishii Y, Yamaoka H, Toh K, Kikuchi K. Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gann. 1976;67:115. [PubMed] [Google Scholar]
  • 11.Jerrells TR, Dean JH, Richardson G, Cannon GB, Herberman RB. Increased monocyte-mediated cytostasis of lymphoid cell lines in breast and lung cancer patients. Int J Cancer. 1979;23:768. doi: 10.1002/ijc.2910230606. [DOI] [PubMed] [Google Scholar]
  • 12.Jett JR, Mantovani A, Herberman RB. Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol. 1980;54:425. doi: 10.1016/0008-8749(80)90222-1. [DOI] [PubMed] [Google Scholar]
  • 13.Mantovani A, Dean JH, Jerrells TR, Herberman RB. Augmentation of tumoricidal activity of human monocytes and macrophages by lymphokines. Int J Cancer. 1980;25:691. doi: 10.1002/ijc.2910250602. [DOI] [PubMed] [Google Scholar]
  • 14.Mantovani A, Polentarutti N, Giuseppe P, Shavit ZB, Vecchi A, Bolis G, Mangioni C. Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors. J Natl Cancer Inst. 1980;64:1307. doi: 10.1093/jnci/64.6.1307. [DOI] [PubMed] [Google Scholar]
  • 15.Mantovani A, Taglibue A, Dean JH, Jerrells TR, Herberman RB. Cytolytic activity of circulating human monocytes on transformed and untransformed human fibroblasts. Int J Cancer. 1979;23:28. doi: 10.1002/ijc.2910230106. [DOI] [PubMed] [Google Scholar]
  • 16.Murayama T, Natsuume-Sakai S, Ryoyama K, Koshimura S. Studies of the properties of a streptococcal preparation, OK-432 (NSC-B116209), as an immunopotentiator. II. Mechanisms of macrophage activation by OK-432. Cancer Immunol Immunother. 1982;12:141. [Google Scholar]
  • 17.Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol. 1967;11:323. doi: 10.1111/j.1348-0421.1967.tb00350.x. [DOI] [PubMed] [Google Scholar]
  • 18.Pross HF, Baines MG. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. I. The effect of malignant disease. Int J Cancer. 1976;18:593. doi: 10.1002/ijc.2910180508. [DOI] [PubMed] [Google Scholar]
  • 19.Pross HF, Baines MG. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. VI. A brief review. Cancer Immunol Immunother. 1977;3:75. doi: 10.1002/ijc.2910200306. [DOI] [PubMed] [Google Scholar]
  • 20.Rinehart JJ, Vessella R, Lange P, Kaplan ME, Gormus GJ. Characterization and comparison of human monocyte- and macrophage-induced tumor cell cytotoxicity. J Lab Clin Med. 1979;93:361. [PubMed] [Google Scholar]
  • 21.Takasugi M, Ramseyre A, Takasugi J. Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res. 1977;37:413. [PubMed] [Google Scholar]
  • 22.Uchida A, Hoshino T. Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer. 1980;45:476. doi: 10.1002/1097-0142(19800201)45:3<476::aid-cncr2820450311>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  • 23.Uchida A, Hoshino T. Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapy. Int J Cancer. 1980;26:401. doi: 10.1002/ijc.2910260403. [DOI] [PubMed] [Google Scholar]
  • 24.Uchida A, Micksche M. In vitro augmentation of natural killing activity by OK-432. Int J Immunopharmac. 1981;3:365. doi: 10.1016/0192-0561(81)90032-1. [DOI] [PubMed] [Google Scholar]
  • 25.Uchida A, Micksche M. NK cells and other natural effector cells. New York: Academic Press; 1982. Augmentation of human natural killing activity by OK-432; p. 431. [Google Scholar]
  • 26.Uchida A, Micksche M. Intrapleural administration of OK432 in cancer patients: Activation of NK cells and reduction of suppressor cells. Int J Cancer. 1983;31:1. doi: 10.1002/ijc.2910310102. [DOI] [PubMed] [Google Scholar]
  • 27.Yanagawa E. Study on the immunological reactivity of cancer patients. I. Cytostatic activity of peripheral blood monocytes against allogeneic cultured tumor cells in cancer patients. Jpn J Surg Soc. 1982;83:27. [Google Scholar]
  • 28.Yanagawa E, Yasumoto K, Manabe H, Nagano N, Hirota N, Ohta M, Hattori T, Azuma I, Yamamura Y. Cytostatic activity of peripheral blood monocytes against bronchogenic carcinoma cells in patients with lung cancer. Gann. 1979;70:533. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES